sickle cell disease

Real-World Data Confirms Proximal Complement Inhibition in PNH

Real-world evidence presented at EHA 2026 validates the efficacy and safety of proximal complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH).

Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives

EHA 2026 highlighted real-world strategies for optimising transplant outcomes in haemoglobinopathies, focusing on conditioning and graft sources.

Inflammation Drives Sickle Cell Disease Pathophysiology

Sickle cell disease (SCD) is characterised by chronic inflammation, contributing to vaso-occlusive crises and organ damage. Targeting inflammatory pathways may offer therapeutic avenues.